880348-28-7

Upstream product

• 880386-25-4 3-bromo-4-fluoro-L-phenylalanine 
• 108-24-7 acetic anhydride 
• 1361513-62-3 (Z)-2-acetamido-3-(3-bromo-4-fluorophenyl)acrylic acid 
• 1361513-61-2 (Z)-methyl 2-acetamido-3-(3-bromo-4-fluorophenyl)acrylate 
• 77771-02-9 3-bromo-4-fluorobenzaldehyde 
• 880348-26-5 2-acetylamino-3-(3-bromo-4-fluorophenyl)acrylic acid 

Downstream Products

• 880386-25-4 3-bromo-4-fluoro-L-phenylalanine 
• 1297599-47-3 2-(2-amino-4,5-dichlorobenzoylamino)-3-(3-bromo-4-fluorophenyl)propionic acid 
• 1297599-48-4 2-{3-[2-(3-bromo-4-fluorophenyl)-1-carboxyethyl]ureido}-4,5-dichlorobenzoic acid 
• 880386-23-2 C₁₀H₁₁BrFNO₂ 

Relevant academic research and scientific papers

Protecting-group-free synthesis of a dual CCK1/CCK2 receptor antagonist

In our pursuit of an efficient, protecting-group-free synthesis of the dual CCK1/CCK2 receptor antagonist 1, we have developed chemoselective conditions for sulfonamide formation reaction in pure water and a PhNMe2 mediated carboxamide formatio

Enantioselective access to chiral drugs by using asymmetric hydrogenation catalyzed by Rh(P-OP) complexes

P-OP art: Rhodium complexes of P-OP ligands serve as highly efficient and enantioselective catalysts in asymmetric hydrogenation leading to various valuable pharmaceutical building blocks and several direct precursors of chiral drugs such as LY2497282, la

SULFONAMIDE COMPOUNDS

Certain sulfonamide compounds are dual CCK1/CCK2 inhibitors useful in the treatment of CCK1/CCK2 mediated diseases.